GlobeNewswire

Overall Survival (n=28, median follow-up 4.3 months)

Overall Survival (n=28, median follow-up 4.3 months)

As of Jan 6, 2019; evaluable patients include patients completing one cycle of therapy
Tyme Technologies, Inc.
Format

JPEG

Source

Tyme Technologies, Inc.

Downloads